罗格列酮二甲双胍联合治疗糖尿病肾病疗效观察

Observation on the therapeutic effect of rosiglitazone combined with metformin on diabetic nephrophathy

目的观察罗格列酮与二甲双胍联合用药对2型糖尿病合并早期糖尿病肾病尿微量白蛋白排泄率的治疗效果。方法采用开放、随机、平行对照方法将78名2型糖尿病合并早期糖尿病肾病患者分为两组。治疗组40例,在原治疗基础上,加用口服罗格列酮和二甲双胍;对照组38例,继续原降糖药治疗。疗程16周。观察治疗前后空腹血糖、餐后2h血糖、糖化血红蛋白、血清胰岛素及尿微量白蛋白排泄率的变化。结果两组空腹及餐后2h血糖、糖化血红蛋白均显著下降。在降低血清胰岛素、尿微量白蛋白排泄率方面,治疗组显著优于对照组。结论罗格列酮与二甲双胍联合用药可降低2型糖尿病合并早期糖尿病肾病尿微量白蛋白排泄率。

Objective To observe the effects of rosiglitazone combined with metformin on the type 2 diabetes patients complicated with early diabetic nephropathy. Methods 78 type 2 diabetes patients with early diabetic nephropathy were divided randomly into control group consisted of 38 cases treated with pypoglycemic agent and observation group consisted of 40 cases treated with hypoglycemic agent plus rosiglitazone and mefformin over a course of 16 weeks. Fasting blood glucose, 2 - hour postprandial blood glucose, glycosylated hemoglobinA1 （c）, serum insulin, urinary microalbmnin excretory rate were determined before and after 16 weeks. Results FBG.P2FBG.HbAlc were significantly decreased in both groups. Compared with control group, the level of serum insulin and urinary micrualbumin excretory rate were significantly decreased in observation group （ P 〈 0.01 ）. Conclusion The rusiglitazone in combination with mefformin can reduce urinary micrualbumin excretory rate in type 2 diabetes patients complicated with early diabetic nephropathy.